DOCSLIB.ORG

Back Matter (PDF)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

SUBJECT INDEX 1961 ABS -ADR ABSORPTION (1) morphine addiction 8535 concentration effects 8516 morphine withdrawal 8535 local anesthetics 8516 plasma l7-OHCS levels 8535 mucous membrane applications 8516 urinary l7-OHCS excretion 8535 relative toxicities 8516 ADRENAL GLANDS (11) ACENOCOUNAROL (sIN’rRoM) (2) adrenal vein effluents 8534 oxygen consumption 8533 anesthetized rats 8551 rat liver slices 8533 ascorbic acid content 8551 ACETIC ACID (3) catecholamine output 8534 concentration 8547 histamine-induced stress 8551 E. coli 8547 medullary hormones 8534 inhibitor activity 8547 morphine inhibitor activity 8551 ionized acid 8547 nalorphine-morphine oxidative metabolism 8547 antagonism 8551 unionized acid 8547 selective secretion 8534 ACETYLSALICYLIC ACID (4) ADRENAL MEDULLA (12) laboratory animals 8532 catecholamine release 8506 metabolism 8532 triethyltin 8506 oral toxicity 8532 ADRENALECTONY (13) ACETYLSTROPHANTHIDIN (5) amphetamine toxicity 8557 DCI influence 8558 blood pressure 8526 heart arrhythmias 8558 8527 isolated perfused heart 8558 ganglionic blockade 8509 ACIDOSIS, METABOLIC (6) McN-A-343 response 8526 aminophylline response 8553 neostigmine pressor response 8509 electrolyte excretion 8553 senecioylcholine response 8527 unanesthetized dog 8553 stressed animals 8557 ACTH (7) sympathectomy 8509 adrenal ascorbic acid 8551 tissue catecholamine content 8506 anesthetized rats 8551 beta-TM-lO 8509 blood eosinophiles 8535 triethyltin 8506 central nervous system 8551 A.DRENERGIC AGENTS (14) histamine-induced secretion 8551 adrenergic blocking agents 8510 human subjects 8535 blood flow responses 8510 morphine addiction 8535 catecholamines 8554 morphine inhibitor activity 8551 curarized animals 8554 nalorphine-morphine EEC 8554 antagonism 8551 epinephrine 8510 plasma 17-OHCS levels 8535 intra-arterial injections 8510 stress response 8551 levarterenol 8510 ADENOSINE TRIPHOSPHATE (8) skeletal muscle bed 8510 contractile tension 8525 ADRENERGIC BLOCKADE (15) glycerol-extracted fibers 8525 blood pressure 8527 heart muscle 8525 dibenamine 8509 “relaxing factor” 8525 ganglionic blockade 8509 ADENYL COMPOUNDS (9) neostigmine pressor response 8509 “crude burn” material 8520 phenoxybenzamine 8509 skin burns 8520 phentolamine 8509 ADRENAL CORTEX (10) 8527 functional activity 8535 piperoxan 8509 human subjects 8535 senecioylcholine response 8527 S-I SUBJECT INDEX ADR-AMP VOL. 132 ADRENERCIC BLOCKING AGENTS (16) Gamma-AMINOBUTYRIC ACID (20) action duration 8510 autonomic ganglia 8508 adrenergic agents 8510 concentration effect 8508 albino rabbits 8555 depressant activity 8508 amphetamine stimulation hexamethonium comparison 8508 pattern 8555 intra-arterial injection 8508 amphetamine toxicity 8557 synaptic transmission 8508 azapetine 8510 tachyphylaxis 8508 8554 8555 AMINOPHYLLINE (21) blood flow responses 8510 diuretic effect 8553 catecholamine stimulant hydrochlorothiazi de response 8554 pretreatment 8553 chlorpromazine 8554 kidney function 8553 8555 mercaptomerin pretreatment 8553 conductance 8510 metabolic acidosis 8553 cortical electrogenesis 8554 metabolic alkalosis 8553 8555 renal electrolyte excretion 8553 curarized animals 8554 specific refractoriness 8553 dibenamine 8555 unanesthetized dogs 8553 dibozane 8510 AMPHETAMINE (22) dihydroergotamine 8554 adaptation influence 8518 8555 adrenalectomy 8557 EEC patterns 8554 adrenergic blocking agents 8555 8555 aggregated mice 8518 hypotensive potency 8510 albino rabbits 8555 intra-arterial injection 8510 body temperature 8518 isoproterenol stimulant chlorpromazine pretreatment 8557 action 8554 cortical electrogenesis 8555 pentobarbital pretreatment 8555 EEC stimulation pattern #{149} 8555 phenoxybenzamine 8510 isolated mice 8518 8554 8555 lethal toxicity 8518 phenoxybenzamine pretreatment 8557 8557 phentolamine 8554 pentobarbital pretreatment 8555 8555 pentylenetetrazol seizure skeletal muscle bed 8510 threshold 8518 stressed animals 8557 phenoxybenzamine pretreatment 8557 ADRENOCORTICAL STEROIDS (17) stressed animals 8557 adrenalectomized rats 8536 toxicity mechanism 8518 anti-inflammatory action 8536 d-AMPHETAMINE (23) body weight changes 8536 albino mice 8517 electrolyte excretion 8536 atropine-induced augmentation 8517 erythrocyte Fe59 harmaline pretreatment 8539 incorporation 8536 imipratnine pretreatment 8529 thymolytic activity 8536 iproniazid pretreatment 8529 ALKALOSIS, METABOLIC (18) 8539 aminophylline response 8553 metabolic destruction in vivo 8529 electrolyte excretion 8553 motor activity 8517 unanesthetized dogs 8553 pyridindole II pretreatment 8539 AMINO ACIDS-C14 (19) shock avoidance responses 8517 E. coli cell fractions 8505 spider sensitivity 8529 protein distribution 8505 spontaneous activity 8539 RNA incorporation 8505 stimulatory response 8539 web-building behavior 8529 S-2 SUBJECT INDEX 1961 AMA-ANT ANALGESIA (24) lethal toxicity 8512 albino mice 8556 neuromuscular block 8512 antiparkinsonian agents 8556 organophosphorus compounds 8512 tremorine induced 8556 oxime-atropine treatment 8512 ANALGESICS (25) ANTICHOLINESTERASES (32) EEC 8515 atropine blocking action 8509 evoked brain potentials 8515 ganglionic blockade 8509 morphine 8515 neostigmine pressor response 8509 8540 neuromuscular transmission 8514 nal orphine 8515 physostigmine comparison 8509 phenazocine 8540 quaternary ammonium compounds 8514 potency ratio 8540 twitch potentiating potencies 8514 thermal radiation test 8540 ANTICOAGULANTS (33) tooth pulp stimulation 8515 oxygen consumption 8533 ANESTHETICS, LOCAL (26) rat liver slices 8533 action duration 8516 ANTICONVULSANTS (34) anesthetic efficiencies 8516 albino mice 8556 concentration effects 8516 chlorphenoxamine 8556 intranasal application 8516 maximal PTZ seizures 8556 intratracheal application 8516 MES test 8556 intravenous administration 8516 nicotine convulsions 8556 intravesical application 8516 PTZ threshold test 8556 rabbit nasal mucosa 8516 strychnine lethality 8556 rabbit sneeze reflex 8516 ANTIEMETICS (35) relative safety 8516 comparative potency 8540 toxici ties 8516 drug-induced emesis 8540 ANGIOTONIN (27) morphine 8540 arterial strips 8507 phenazoc me 8540 mecamylamine potentiation 8507 ANTIHISTAMINES (36) TEA potentiation 8507 heparin hydrolysates 8513 ANOXIA (28) pyri lamine 8513 cat papillary muscles 8524 smooth muscle contraction 8513 ouabain response 8524 ANTI-INFLAMMATORY AGENTS (37) ANTIARRHYTIINIA AGENTS (29) adrenalectomized rats 8536 acetylstrophanthidin adrenocortical steroids 8536 ventricular tachycardia 8559 asbestos granuloma test 8536 dichloroi soproterenol 8558 20-cobalto-delta-l- isolated rabbit hearts 8559 hydrocorti sone 8536 ouabain-induced arrhythmia 8558 cobaltous chloride procaine ethylchloride 8559 hexahyd rate 8536 procaine ethylchloride cation 8559 granuloma pouch exudate 8536 procaine hydrochloride 8559 hydrocort i sone 8536 procaine ionization 8559 predni so lone 8536 related dichloro compounds 8558 ANTIPARKINSONIAN AGENTS (38) ANTIBIOTICS (30) adult dogs 8556 cell suspensions 8505 albino mice 8556 chloramphenicol 8505 anticholinergic effects 8556 E. coli 8505 canine chorea 8556 ANTICHOLINESTERASE INTOXICATION, chlorphenoxamine 8556 EXPERIMENTAL (31) comparative activities 8556 albino rabbits 8512 flexor spasm syndrome 8556 S-3 SUBJECT INDEX ANT -BLO VOL. 132 keithon 8556 BARBITAL (45) nicotine convulsions 8556 barbital pretreatment 8531 tremorine analgesia 8556 chlorcyclizine pretreatment 8531 tremorine tremors 8556 metabolism rate 8546 ANTITREMOR AGENTS (39) nikethamide treated animals 8546 albino mice 8556 orphenadrine pretreatment 8531 chlorphenoxamine 8556 phenobarbital pretreatment 8531 keithon 8556 rat liver microsomes 8546 tremorine tremors 8556 sleeping time 8531 ASCORBIC ACID (40) 8546 adrenal gland content 8551 BARBITURATES (46) anesthetized rats 8551 adult rats 8546 histamine response 8551 chlorcyclizine pretreatment 8531 morphine inhibitor activity 8551 metabolism 8531 nalorphine -morphine 8546 antagonism 8551 nikethamide pretreatment 8546 ATROPINE (41) sleeping time 8546 amphetamine reactions 8517 weanling rats 8546 anticholinesterase poisoning 8512 BARIUM (47) anticonvulsant activity 8556 arterial strips 8507 antidotal effect 8512 mecamylamine potentiation 8507 antitremor activity 8556 TEA potentiation 8507 augmentation effect 8517 BENZTROPINE (48) autonomic ganglia 8526 anticonvulsant activity 8556 avoidance responding 8517 antitremor activity 8556 blocking effect 8509 tremorine analgesia 8556 8526 BIOASSAY (49) hexamethonium pretreatment 8509 active substance release 8520 McN-A-343 stimulant activity 8526 discrimination index 8520 motor activity 8517 skin burns 8520 neostigmine pressor response 8509 smooth muscle preparations 8520 oxime adjuvant action 8512 subcutaneous pocket tremorine analgesia 8556 diffusates 8520 AUTONOMIC GANGLIA (42) BISHYDROXYCOUNARIN (DICuMAROL) gamma-aminobutyric acid 8508 Cl4-labeled (50)8533 atropine blocking action 8526 liver cell fractions 8533 decerebrate cats 8508 oxygen consumption 8533 differential sensitivity 8508 radioactivity distribution 8533 McN-A-343 stimulation 8526 rat liver slices 8533 synaptic transmission 8508 BLOOD EOSINOPHILES (51) AUTONOMIC NERVOUS SYSTEM, abstinence intensity 8535 CENTRAL (43) ACTH response 8535 chlorpromazine 8528 human subjects 8535 comparative effects 8528 morphine addiction 8535 parasympathetic activity 8528 morphine withdrawal 8535 re serpine 8528 BLOOD FLOW (52) tetrabenazine 8528 adrenergic agents 8510 AZAPETINE (44) adrenergic blocking agents 8510 adrenergic blocking agent 8510 anesthetized dogs 8510 blood flow responses
Recommended publications
  • United States Patent (19) 11 Patent Number: 4,540,564 Bodor (45) Date of Patent: Sep

    United States Patent (19) 11 Patent Number: 4,540,564 Bodor (45) Date of Patent: Sep

    United States Patent (19) 11 Patent Number: 4,540,564 Bodor (45) Date of Patent: Sep. 10, 1985 54 BRAIN-SPECIFICDRUG DELIVERY 57 ABSTRACT 75 Inventor: Nicholas S. Bodor, Gainesville, Fla. The subject compounds, which are adapted for the site-specific/sustained delivery of centrally acting drug 73) Assignee: University of Florida, Gainesville, species to the brain, are: Fla. (a) compounds of the formula 21 Appl. No.: 516,382 22 Filed: Jul. 22, 1983 D-DHC) (I) Related U.S. Application Data wherein D is a centrally acting drug species, and 63 Continuation-in-part of Ser. No. 379,316, May 18, DHC is the reduced, biooxidizable, blood-brain 1982, Pat. No. 4,479,932, Ser. No. 461,543, Jan. 27, barrier penetrating lipoidal form of a dihydropyri 1983, , and Ser. No. 475,493, Mar. 15, 1983, , said Ser. dine - pyridinium salt redox carrier, with the No. 46,543, and Ser. No. 475,493, each is a continua proviso that when DHC) is tion-in-part of Ser. No. 379,316. 30 Foreign Application Priority Data O May 12, 1983 WO, PCT Int'l Appl. ......... WO83/00725 May 16, 1983 ICA) Canada ................................... 42892 51) Int. Cl...................... A61K 49/00; A61K 31/58; r’sN CO7J 17/00 52 U.S. Cl. ..................................... 424/9; 260/239.5; R 514/176 58 Field of Search .................. 424/9, 241; 260/239.5 wherein R is lower alkyl or benzyl and D is a drug species containing a single NH2 or OH func 56 References Cited tional group, the single OH group when present U.S.
  • Wo 2010/075090 A2

    Wo 2010/075090 A2

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 1 July 2010 (01.07.2010) WO 2010/075090 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 409/14 (2006.01) A61K 31/7028 (2006.01) kind of national protection available): AE, AG, AL, AM, C07D 409/12 (2006.01) A61P 11/06 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2009/068073 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 15 December 2009 (15.12.2009) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, (26) Publication Language: English TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/122,478 15 December 2008 (15.12.2008) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): AUS- ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, PEX PHARMACEUTICALS, INC.
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1

    Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1

    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
  • Prohibited Substances List

    Prohibited Substances List

    Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR). Neither the List nor the EADCM Regulations are in current usage. Both come into effect on 1 January 2010. The current list of FEI prohibited substances remains in effect until 31 December 2009 and can be found at Annex II Vet Regs (11th edition) Changes in this List : Shaded row means that either removed or allowed at certain limits only SUBSTANCE ACTIVITY Banned Substances 1 Acebutolol Beta blocker 2 Acefylline Bronchodilator 3 Acemetacin NSAID 4 Acenocoumarol Anticoagulant 5 Acetanilid Analgesic/anti-pyretic 6 Acetohexamide Pancreatic stimulant 7 Acetominophen (Paracetamol) Analgesic/anti-pyretic 8 Acetophenazine Antipsychotic 9 Acetylmorphine Narcotic 10 Adinazolam Anxiolytic 11 Adiphenine Anti-spasmodic 12 Adrafinil Stimulant 13 Adrenaline Stimulant 14 Adrenochrome Haemostatic 15 Alclofenac NSAID 16 Alcuronium Muscle relaxant 17 Aldosterone Hormone 18 Alfentanil Narcotic 19 Allopurinol Xanthine oxidase inhibitor (anti-hyperuricaemia) 20 Almotriptan 5 HT agonist (anti-migraine) 21 Alphadolone acetate Neurosteriod 22 Alphaprodine Opiod analgesic 23 Alpidem Anxiolytic 24 Alprazolam Anxiolytic 25 Alprenolol Beta blocker 26 Althesin IV anaesthetic 27 Althiazide Diuretic 28 Altrenogest (in males and gelidngs) Oestrus suppression 29 Alverine Antispasmodic 30 Amantadine Dopaminergic 31 Ambenonium Cholinesterase inhibition 32 Ambucetamide Antispasmodic 33 Amethocaine Local anaesthetic 34 Amfepramone Stimulant 35 Amfetaminil Stimulant 36 Amidephrine Vasoconstrictor 37 Amiloride Diuretic 1 Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR).
  • Recent Advances in the Treatment of Parkinson's Disease

    Recent Advances in the Treatment of Parkinson's Disease

    Recent advances in the treatment of Parkinsonism Parkinsons disease RICHARD J. MARTOCCI, D.O. Highland Park, Michigan ticholinergic drugs conventionally used to treat par- kinsonism, levodopa was three-and-a-half times as Although there are both medical and effective in relieving symptoms. However, the surgical methods of treating treatment of paralysis agitans, whether medical or parkinsonism, medical therapy should surgical, remains purely palliative and never is cura- be tried first and surgical measures tive. reserved for patients who do not respond. Anticholinergic drugs may be Pathophysiologic and biochemical aspects combined with an antihistamine when The pathologic alterations in parkinsonism the symptoms are mild, and levodopa (paralysis agitans) most consistently affect the zona used alone or with another drug when compacta2 of the substantia nigra with formation of the disease is moderate to severe. The Lewy bodies, or inclusion bodies, and neurofibril- side effects of levodopa are lary tangles3 such as those in Alzheimers disease and troublesome, and the clinical program other forms of senile atrophy. Histochemical studies must be adjusted constantly to achieve using fluorescent techniques have shown that maximum benefits and minimum side dopamine is almost nonexistent in the neostriatum effects. Pyridoxine reverses side effects and substantia nigra. Dopamine, a catecholamine, but also the benefits of levodopa. Use of has proved to be a neurohumeral transmitter. This a peripheral decarboxylase inhibitor suggests that in parkinsonism there is a decrease in may permit reduction in the dose of ability of affected brain tissue to form dopamine, levodopa to a point that side effects can and from 80 to 90 percent of dopamine in the brain be minimal.
  • (19) United States (12) Patent Application Publication (10) Pub

    (19) United States (12) Patent Application Publication (10) Pub

    US 20130210835A1 (19) United States (12) Patent Application Publication (10) Pub. N0.2 US 2013/0210835 A1 Mitchell (43) Pub. Date: Aug. 15, 2013 (54) PHARMACEUTICAL COMPOSITIONS Publication Classi?cation (75) Inventor: Odes W. Mitchell; Arlington, TX (U S) (51) Int. Cl. A61K31/137 (2006.01) _ A611; 31/4402 (2006.01) (73) Ass1gnee: GM PHARMACEUTICAL, INC, A61K 31/485 (200601) Arhngton, TX (Us) A611; 31/09 (2006.01) _ A611; 31/495 (2006.01) (21) App1.No.. 13/703,584 A61K31/505 (200601) 22 PCT P1 d: J .13 2011 (52) us Cl ( ) 1e “n ’ CPC ........... .. A611; 31/137 (2013.01); A611;31/495 (86) PCT NO. PCT/“11,4031 (2013.01); A611;31/505 (2013.01); A611; 31/485 (2013.01); A611; 31/09 (2013.01); § 371 (0)0). A611;31/4402 (2013.01) (2), (4) Date: Feb- 2, 2013 USPC .... .. 514/255.04; 564/355; 514/653; 544/396; 544/332; 514/275; 546/74; 514/289; 514/282; Related US. Application Data 514657; 514652 (60) Provisional application No. 61/354,061; ?led on Jun. (57) ABSTRACT 11; 2010; provisional application No. 61/354,057; A composition of an antitussive; a decongestant; or an anti ?led on Jun. 11; 2010; provisional application No. histamine to treat respiratory and oral pharyngeal congestion 61/354,053; ?led on Jun. 11,2010. and related symptoms in a patient. US 2013/0210835 A1 Aug. 15,2013 PHARMACEUTICAL COMPOSITIONS mucus build-up to clear congestion in the air passages. Symp toms due to allergies or allergens are often treated With an CROSS-REFERENCES TO RELATED antihistamine.
  • Drug and Medication Classification Schedule

    Drug and Medication Classification Schedule

    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine
  • Pharmaceuticals As Environmental Contaminants

    Pharmaceuticals As Environmental Contaminants

    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available

    BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available

    BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] BMJ Open Pediatric drug utilization in the Western Pacific region: Australia, Japan, South Korea, Hong Kong and Taiwan Journal: BMJ Open ManuscriptFor ID peerbmjopen-2019-032426 review only Article Type: Research Date Submitted by the 27-Jun-2019 Author: Complete List of Authors: Brauer, Ruth; University College London, Research Department of Practice and Policy, School of Pharmacy Wong, Ian; University College London, Research Department of Practice and Policy, School of Pharmacy; University of Hong Kong, Centre for Safe Medication Practice and Research, Department
  • Vr Meds Ex01 3B 0825S Coding Manual Supplement Page 1

    Vr Meds Ex01 3B 0825S Coding Manual Supplement Page 1

    vr_meds_ex01_3b_0825s Coding Manual Supplement MEDNAME OTHER_CODE ATC_CODE SYSTEM THER_GP PHRM_GP CHEM_GP SODIUM FLUORIDE A12CD01 A01AA01 A A01 A01A A01AA SODIUM MONOFLUOROPHOSPHATE A12CD02 A01AA02 A A01 A01A A01AA HYDROGEN PEROXIDE D08AX01 A01AB02 A A01 A01A A01AB HYDROGEN PEROXIDE S02AA06 A01AB02 A A01 A01A A01AB CHLORHEXIDINE B05CA02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D08AC02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D09AA12 A01AB03 A A01 A01A A01AB CHLORHEXIDINE R02AA05 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S01AX09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S02AA09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S03AA04 A01AB03 A A01 A01A A01AB AMPHOTERICIN B A07AA07 A01AB04 A A01 A01A A01AB AMPHOTERICIN B G01AA03 A01AB04 A A01 A01A A01AB AMPHOTERICIN B J02AA01 A01AB04 A A01 A01A A01AB POLYNOXYLIN D01AE05 A01AB05 A A01 A01A A01AB OXYQUINOLINE D08AH03 A01AB07 A A01 A01A A01AB OXYQUINOLINE G01AC30 A01AB07 A A01 A01A A01AB OXYQUINOLINE R02AA14 A01AB07 A A01 A01A A01AB NEOMYCIN A07AA01 A01AB08 A A01 A01A A01AB NEOMYCIN B05CA09 A01AB08 A A01 A01A A01AB NEOMYCIN D06AX04 A01AB08 A A01 A01A A01AB NEOMYCIN J01GB05 A01AB08 A A01 A01A A01AB NEOMYCIN R02AB01 A01AB08 A A01 A01A A01AB NEOMYCIN S01AA03 A01AB08 A A01 A01A A01AB NEOMYCIN S02AA07 A01AB08 A A01 A01A A01AB NEOMYCIN S03AA01 A01AB08 A A01 A01A A01AB MICONAZOLE A07AC01 A01AB09 A A01 A01A A01AB MICONAZOLE D01AC02 A01AB09 A A01 A01A A01AB MICONAZOLE G01AF04 A01AB09 A A01 A01A A01AB MICONAZOLE J02AB01 A01AB09 A A01 A01A A01AB MICONAZOLE S02AA13 A01AB09 A A01 A01A A01AB NATAMYCIN A07AA03 A01AB10 A A01
  • Biperiden and Chlorphenoxamine) in Various Dosage Forms by Spectrophotometry

    Biperiden and Chlorphenoxamine) in Various Dosage Forms by Spectrophotometry

    International Journal of Chemical and Analytical Science ISSN: 0976-1206 Research Article www.ijcas.info Simultaneous Determination of some anticholinergic drugs (Biperiden and Chlorphenoxamine) in Various Dosage forms by Spectrophotometry Issa FAA1, EL-Helbawy SM2 and Abed EL- Magied AM2* 1Chemistry Department, faculty of science, Menoufia University 2Medico-Legal organization, Ministry of Justice, Cairo, Egypt Simple and rapid spectrophotometric procedures were established for quantization of biperiden hydrochloride (BPN) and chlorphenoxamine hydrochloride (CPA). The procedures are based on the reaction between the examined drugs BPN and CPA and picric acid (I), alizarin (II), bromothymol blue (III) and chlorophenol red (IV) producing ion-associates which can be measured at the optimum wavelength. The optimization of the reaction conditions was investigated. Beer’s law is obeyed in the concentration ranges 58.8 –166.4 µgml−1. The molar absorptivity, Sandell sensitivity are also calculated. The correlation coefficient was ≥0.9996 (n = 6) with a relative standard deviation (R.S.D.) ≤1.35 for four determinations. The methods are successfully applied to determine of BPN and CPA in pharmaceutical formulations. Keywords: Spectrophotometry, Ion-Associates, Drugs, Biperiden, Chlorphenoxamine INTRODUCTION MATERIALS AND METHODS Biperiden hydrochloride (BPN) is α-Bicyclo [2.2.1] hept–5–en– Apparatus: The spectral measurements were carried out by 2–yl-α-phenyl–1–piperidinepropanol. Chlorphenoxamine using U.V-visible spectrophotometer (Helios Alpha) with a hydrochloride (CPA) is 2-[1-(4-Chlorophenyl)-1–phenyl- 10mm quartz cell, optical path length was used. phenylethoxy]-N, N-dimethylethanamine. They are a weak peripheral anticholinergic[1,2] Agent. It has, therefore, some Reagents: Picric acid 2,4,6 tri nitro phenol (I), Alizarin 1,2 di antisecretory, antispasmodic, mydriatic and antihistaminic hydroxy anthraquinone (II), bromothymol blue 3,3 effects.
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued

    Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued

    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0